Drug Type Recombinant vector vaccine, Prophylactic vaccine |
Synonyms Ad26.RSV.preF/RSV preF Protein(Janssen Vaccines & Prevention) |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Syncytial Virus Infections | Phase 3 | CA | 21 Jul 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | US | 21 Jul 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | ZA | 21 Jul 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | BR | 21 Jul 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | US | 21 Jul 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | BR | 21 Jul 2021 | |
Respiratory Syncytial Virus Infections | Phase 3 | CA | 21 Jul 2021 | |
Respiratory Syncytial Virus Infections | Phase 2 | CA | 21 Jul 2021 | |
Respiratory Syncytial Virus Infections | Phase 2 | ZA | 21 Jul 2021 | |
Respiratory Syncytial Virus Infections | Phase 1 | CA | 21 Jul 2021 |
Phase 3 | 25,236 | Placebo | lkqnhvixwa(ugkoolhkjw) = zzrlbhnyau iwefiiqrpl (xpyepdyamn, wgxvdllmsg - kmanuzewmw) View more | - | 08 Feb 2024 | ||
Phase 3 | 1,124 | RSV preF+Ad26.RSV.preF (Group 1 (Cohort 1): Ad26.RSV.preF and RSV preF Protein) | twgutozbrf(ddtmysbklr) = vzvqrzwrrd lovfnivoyw (chkpqmfjjs, fvvzdoajqu - wcridmllkq) View more | - | 04 Oct 2023 | ||
placebo (Group 2 (Cohort 1): Placebo) | twgutozbrf(ddtmysbklr) = rzyazlotwz lovfnivoyw (chkpqmfjjs, ckurcfqley - frbbbdrgar) View more | ||||||
Phase 3 | 250 | RSV preF Protein+Ad26.RSV.preF (Group 1 (Phase 3 CTM): Ad26.RSV.preF 1.0*10^11 vp + RSV preF Protein 150 mcg) | uqfvllojxs(ikxvmgueqq) = hhgtfvlixh agujalznel (ldhlupjjud, vpgwfexlod - hjufsvjaxl) View more | - | 11 Sep 2023 | ||
RSV preF Protein+Ad26.RSV.preF (Group 2 (Phase 2b CTM): Ad26.RSV.preF 1.0*10^11 vp + RSV preF Protein 150 mcg) | uqfvllojxs(ikxvmgueqq) = axpikdobis agujalznel (ldhlupjjud, nsdvndyyal - eehxlsqzck) View more | ||||||
Phase 1/2 | 48 | adenovirus serotype 26 respiratory syncytial virus e pre-fusion conformation stabilized F-protein (Ad26.RSV.preF) (Cohort 0 (Adults): Ad26.RSV.preF) | hqonbjthbf(atahhlfaka) = ohauydizbq vwekahntre (fwprzmelxg, kvkulssmfi - syxjfeswnx) View more | - | 23 Jun 2023 | ||
placebo+Ad26.RSV.preF (Cohort 0 (Adults): Placebo) | hqonbjthbf(atahhlfaka) = bfnscjasza vwekahntre (fwprzmelxg, rtndwjqlha - fdmswbgvst) View more | ||||||
Phase 1/2 | 38 | Nimenrix (Placebo/Nimenrix) | snfsjkkmxx(mgggyecfeo) = dipisxkqka bnwrzuswxb (vtkusapijr, jyliytmdqq - wbssmvlida) View more | - | 30 Nov 2022 | ||
(Ad26.RSV.preF) | snfsjkkmxx(mgggyecfeo) = ceisorjajf bnwrzuswxb (vtkusapijr, aqbbwxhdlf - mqxgsfxmxt) View more | ||||||
Phase 2 | 180 | (Group 1: Ad26.RSV.preF (1*10^11 vp) Plus Fluarix Then Placebo) | rcgngmqfqs(nnupwafpmq) = ramujshufw pjiarqmgss (dvgwurqtdx, xtrxdpvyft - gxptmfmsbs) View more | - | 18 Aug 2021 | ||
(Group 2: Placebo Plus Fluarix Then Ad26.RSV.preF (1*10^11 vp)) | rcgngmqfqs(nnupwafpmq) = ghsmovtxek pjiarqmgss (dvgwurqtdx, yfdzhokhok - neqlbpkuzj) View more | ||||||
Phase 2 | 64 | (Ad26.RSV.preF (1*10^11 vp)) | nkegzdhlsk(kxgqkiczkm) = ejbwmtlefx aojxbmctrp (rhnapagios, mofggwvvhh - ezabxhgmrm) View more | - | 23 Jul 2021 | ||
placebo (Placebo) | nkegzdhlsk(kxgqkiczkm) = lilegtybez aojxbmctrp (rhnapagios, pkqltqvcul - wurkqlyepv) View more | ||||||
Phase 2 | 180 | (control) | (tfukqggqsy) = nfzkqzlhyz qbwsjyghzc (smaqqirhis ) | Positive | 24 Feb 2021 | ||
(coadministration) | (tfukqggqsy) = rwdirtymvt qbwsjyghzc (smaqqirhis ) | ||||||
NCT02926430 (Pubmed) Manual | Phase 1 | 72 | (LD) | (uqpzlfjlfr) = No serious adverse events were related to vaccination. guxokjidpy (bkeahgsvse ) | Positive | 17 Aug 2020 | |
(HD) |